ConvaTec Group Plc stock (GB00BD3VFW73): FTSE 100 healthcare name with advanced wound care focus

ConvaTec Group Plc, a leader in advanced wound care and ostomy products, maintains steady trading amid FTSE 100 positioning. The stock recently showed a 0.78% dip to around 205p, reflecting ongoing market dynamics for US investors tracking global medtech.

ConvaTec Group Plc shares traded at 205.00p (sell) to 205.40p (buy) with a 1.60p decline or -0.78% change, according to AJ Bell as of May 2026. Originally spun out from Bristol-Myers Squibb, the company specializes in medical products for wound care, ostomy, continence, and infusion care, serving acute hospital and chronic home settings. This price movement highlights its position in the FTSE 100 healthcare sector, relevant for US investors via global medtech exposure.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ConvaTec
• Sector/industry: Healthcare / Advanced Wound Care
• Headquarters/country: United Kingdom
• Core markets: Global, with focus on hospitals and home care
• Key revenue drivers: Wound care (32%), ostomy (28%)
• Home exchange/listing venue: London Stock Exchange (CTEC)
• Trading currency: GBP

ConvaTec Group Plc: core business model

ConvaTec Group Plc designs, manufactures, and markets advanced medical products primarily for wound care, ostomy care, continence care, and infusion devices. Advanced wound care and ostomy supplies represent the largest revenue segments at 32% and 28% of total sales, respectively, based on company disclosures via AJ Bell market research. The business targets both acute-care hospitals and chronic-care home environments, providing solutions for complex wounds, post-surgical needs, and long-term patient management.

This model positions ConvaTec as a key player in the global medtech space, with products supporting burns, ulcers, and infusion therapies. The company's origins as a Bristol-Myers Squibb spin-off have enabled specialized focus, driving consistent demand in aging populations worldwide.

Main revenue and product drivers for ConvaTec Group Plc

Advanced wound care products lead revenue, comprising 32% of total, followed by ostomy at 28%. These segments benefit from innovations in dressings and appliances for chronic conditions prevalent in the US and Europe. Infusion sets and continence solutions round out the portfolio, addressing hospital and home care needs, as detailed in market profiles.

Growth stems from rising chronic disease prevalence and home healthcare trends, with US investors noting exposure to North American markets through product distribution. FTSE 100 inclusion underscores scale, with metrics like a 2.00% dividend yield and 14.19% operating margin reported in index data from Sharecast as of May 2026.

Industry trends and competitive position

The advanced wound care market sees strong demand for OTC and clinical products managing burns, incisions, and ulcers, per sector reports. ConvaTec competes effectively with its specialized portfolio, holding ground in sustainable indices like Euronext Sustainable Europe 120, listing GB00BD3VFW73, via Euronext data. Valuation discussions note potential undervaluation, with estimates suggesting up to 49.3% below intrinsic value in analyses from Simply Wall St.

Why ConvaTec Group Plc matters for US investors

US investors gain indirect exposure to ConvaTec via its global footprint, including North American sales of wound and ostomy products amid rising home care demand. FTSE 100 listing provides liquidity, with GBP trading relevant through ADRs or currency hedges. Healthcare trends like chronic wound management align with US Medicare spending growth.

Conclusion

ConvaTec Group Plc sustains its role in medtech with strong wound care and ostomy drivers, trading steadily on the LSE amid FTSE 100 peers. Recent pricing around 205p reflects market conditions, while segment leadership and index inclusion signal resilience. US investors monitor for global healthcare trends and potential valuation upside, balancing opportunities with currency and sector risks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.